Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

December 31, 2006

Conditions

Fatty LiverHepatitis

Interventions

DRUG

Orlistat (Xenical)

BEHAVIORAL

1400 kcal diet (30% fat)

Trial Locations (2)

Saint Louis University, St Louis

Brooke Army Medical Center, San Antonio

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

St. Louis University

OTHER

NCT00160407 - Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter | Biotech Hunter